[go: up one dir, main page]

WO2025015254A3 - Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment - Google Patents

Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment Download PDF

Info

Publication number
WO2025015254A3
WO2025015254A3 PCT/US2024/037745 US2024037745W WO2025015254A3 WO 2025015254 A3 WO2025015254 A3 WO 2025015254A3 US 2024037745 W US2024037745 W US 2024037745W WO 2025015254 A3 WO2025015254 A3 WO 2025015254A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
cognitive impairment
mild cognitive
relieving
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/037745
Other languages
French (fr)
Other versions
WO2025015254A2 (en
Inventor
Lloyd Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2025015254A2 publication Critical patent/WO2025015254A2/en
Publication of WO2025015254A3 publication Critical patent/WO2025015254A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention recognizes that there is an unmet need for the treatment of mild cognitive impairment. A first aspect of the present invention generally relates to a method of treating, relieving, or alleviating mild cognitive impairment in a subject. A second aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease in a subject. A third aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease Psychosis in a subject. A fourth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease behaviors, aggression, agitation, anger, apathy, or a combination thereof, in a subject. A fifth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Early Onset Alzheimer's Disease in a subject.
PCT/US2024/037745 2023-07-12 2024-07-12 Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment Pending WO2025015254A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363526195P 2023-07-12 2023-07-12
US63/526,195 2023-07-12

Publications (2)

Publication Number Publication Date
WO2025015254A2 WO2025015254A2 (en) 2025-01-16
WO2025015254A3 true WO2025015254A3 (en) 2025-02-20

Family

ID=94216503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/037745 Pending WO2025015254A2 (en) 2023-07-12 2024-07-12 Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment

Country Status (1)

Country Link
WO (1) WO2025015254A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000866A1 (en) * 2018-05-15 2022-01-06 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
US20220041701A1 (en) * 2020-07-23 2022-02-10 Othair Prothena Limited Anti-Abeta Antibodies
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000866A1 (en) * 2018-05-15 2022-01-06 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
US20220041701A1 (en) * 2020-07-23 2022-02-10 Othair Prothena Limited Anti-Abeta Antibodies
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FILIPPO CARACI ∙ GEMMA MOLINARO ∙ GIUSEPPE BATTAGLIA ∙ MARIA LAURA GIUFFRIDA ∙ BARBARA RIOZZI ∙ ANNA TRAFICANTE ∙ VALERIA BRUNO ∙ : "Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies Beta-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective", MOLECULAR PHARMACOLOGY, vol. 79, no. 3, 1 March 2011 (2011-03-01), US , pages 618 - 626, XP009561386, ISSN: 1521-0111, DOI: 10.1124/mol.110.067488 *

Also Published As

Publication number Publication date
WO2025015254A2 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
ZA202201230B (en) Biomarkers and treatments of alzheimer’s disease and mild cognitive impairment
MX2023006205A (en) Photodynamic therapy and diagnosis.
MX2023009613A (en) Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia.
NZ799504A (en) Use of penehyclidine in treatment or prevention of vision-impairing eye diseases
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
IL317382A (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
MX2022003845A (en) Medicinal cognitive treatments.
WO2025015254A3 (en) Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment
MA62935B1 (en) METHODS OF TREATMENT OR PREVENTION OF SPINAL AMYOTROPHY
MX2023000610A (en) Trpv4 inhibitor as therapeutic drug for eye disease.
WO2022011325A8 (en) Methods for the prevention and treatment of hearing loss
ZA202305122B (en) Prophylaxis and treatment of angioedema
Oginski et al. Analysis of the impact of clinical factors on low-intensity extracorporeal shockwave therapy for erectile dysfunction
MX2021015292A (en) Therapeutic interactions of leucomethylthioninium.
WO2023147513A3 (en) Compositions of autophagy modulating agents and uses thereof
Groleau et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated with infliximab
MX2025002727A (en) Scyllo-inositol in combination with immunotherapeutics for the treatment of alzheimer's disease
MX2024006480A (en) Photodynamic therapy and diagnosis.
WO2023107653A3 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
WO2023107552A3 (en) Purines and methods of their use
WO2024031058A3 (en) Compositions and methods to treat neurological diseases
WO2024211300A3 (en) Compositions and methods for the treatment of skin diseases and conditions including eczema
MX2020012116A (en) A synergic ophthalmological composition in low concentration dose effective in the prevention, control, and eradication of presbycia.